The top 12 advances in vascular medicine

Jeffrey W. Olin, James Jang, Michael R. Jaff, Joshua A. Beckman, Thorn Rooke

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


In the past decade, impressive strides have been made in the diagnosis and management of atherosclerotic, aneurysmal, and thromboembolic diseases, thanks in large part to the explosive growth in both vascular biology and clinical vascular medicine. We review what we consider to be the top 12 advances in this field: the discovery of nitric oxide, the metabolic syndrome, new thrombophilic disorders, therapeutic angiogenesis, endoluminal treatment of chronic venous disease, and a variety of drugs, including sildenafil, cilostazol, low-molecular-weight heparins, oral direct thrombin inhibitors, clopidogrel, statins, and angiotensin-converting enzyme inhibitors and angiotensin-receptor blocking agents.

Original languageEnglish (US)
Pages (from-to)II21-II31
JournalJournal of Endovascular Therapy
Issue numberSUPPL. 2
StatePublished - Dec 2004
Externally publishedYes


  • ACE inhibitors
  • Angiogenesis
  • Angiotensin-receptor blocking agents
  • Cilostazol
  • Clopidogrel
  • Low-molecular-weight heparin
  • Metabolic syndrome
  • Nitric oxide
  • Peripheral artery disease
  • Sildenafil
  • Statins
  • Vascular biology
  • Vascular medicine

ASJC Scopus subject areas

  • Surgery
  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'The top 12 advances in vascular medicine'. Together they form a unique fingerprint.

Cite this